Enanta Pharmaceuticals, Inc. Board of Directors

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Dr. Jay R. Luly Ph.D.

Dr. Jay R. Luly Ph.D.

President, CEO & Director

Dr. Scott T. Rottinghaus M.D.

Dr. Scott T. Rottinghaus M.D.

Senior VP & Chief Medical Officer

Ms. Jennifer Viera

Ms. Jennifer Viera

Senior Director of Investor Relations & Corporate Communications

Mr. Paul J. Mellett Jr.

Mr. Paul J. Mellett Jr.

Chief Financial & Administrative Officer

Mr. Brendan Luu

Mr. Brendan Luu

Chief Business Officer

Dr. Yat Sun Or Ph.D.

Dr. Yat Sun Or Ph.D.

Senior VP of Research & Development and Chief Scientific Officer

Ms. Tara Lynn Kieffer Ph.D.

Ms. Tara Lynn Kieffer Ph.D.

Chief Product Strategy Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.